The global tuberculosis diagnostics market size accounted for USD 2.43 billion in 2024, grew to USD 2.56 billion in 2025 and is projected to surpass around USD 4.08 billion by 2034, representing a healthy CAGR of 5.30% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Tuberculosis Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Tuberculosis Diagnostics Market, by Test Type, 2024-2034
8.1.1. Radiographic Method
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Diagnostic Laboratory Methods
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Nucleic Acid Testing
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Phage Assay
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Detection of Latent Infection (Skin Test & IGRA)
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Cytokine Detection Assay
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Detection of Drug Resistance (DST)
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Other Methods
8.1.8.1. Market Revenue and Forecast (2021-2034)
9.1. Tuberculosis Diagnostics Market, by End-use, 2024-2034
9.1.1. Diagnostic Laboratories
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Hospitals & Clinics
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.1.2. Market Revenue and Forecast, by End-use (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End-use (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End-use (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End-use (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End-use (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.5.2. Market Revenue and Forecast, by End-use (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by End-use (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Test Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End-use (2021-2034)
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Becton, Dickinson and Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. F. Hoffmann-La Roche AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Thermo Fisher Scientific Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. BioMérieux SA
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Hain Lifescience GmbH
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. QIAGEN GmbH
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cepheid
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Hologic, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. BD
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample